

Leaked TPP Trade Bill Healthcare Annex. De Facto Privatization of Medicare

By [Stephen Lendman](#)

Global Research, June 12, 2015

Region: [USA](#)

Theme: [Global Economy](#), [Science and Medicine](#)

Proposed Trans-Pacific Partnership (TPP) trade legislation and its companion Transatlantic Trade and Investment Partnership (TTIP) are anti-consumer stealth corporate coup d'etat freedom and ecosystem-destroying measures – nightmarish by any standard.

They let corporate predators establish unrestricted supranational global trade rules overriding national sovereignty and domestic laws.

They serve investor rights at the expense of public ones.

On June 10, [WikiLeaks](#) published the draft **TPP Healthcare Annex (so-called Annex on Transparency and Procedural Fairness for Pharmaceutical Products and Medical Devices)**.

It establishes pharmaceutical and medical device procurement and reimbursement rules government healthcare authorities must follow.

Vague language creates opportunities for drug and medical device companies to challenge Medicare and healthcare program procedures of the 12 TPP-bloc countries.

Consumer friendly policy reforms would be constrained – including the ability of governments to contain rising prices making them unaffordable for millions.

Big Pharma wants profits protected over public health, said WikiLeaks. It wants them maximized.

An earlier Healthcare Annex was released in 2011. Some harmful provisions were removed in the latest version. Global Trade Watch (GTW) says serious questions remain unanswered – vital for people to know, including:

“What guarantees are there that the TPP’s requirements would not override existing procedures for Medicare?”

The US Trade Representative’s Office (USTR) claims Medicare fully complies with TPP provisions.

“Yet (their) ambiguous language...leaves our domestic healthcare policies vulnerable to attack by drug and (medical) device manufacturers,” said GTW.

Could companies use Healthcare Annex provisions to cover expensive products “without a

corresponding benefit to public health,” GTW asked?

Medicare reimburses for “reasonable and necessary” products and treatment. TPP “recognize(s) the value (of drugs and medical devices through the) operation of competitive markets (or their) objectively demonstrated therapeutic significance” – regardless of effectiveness or affordability.

Medicare permits limited reimbursement appeals only. Companies might argue TPP rules permit unrestricted reviews.

“Would the TPP constrain pharmaceutical reform efforts in the US,” asked GTW? Healthcare Annex provisions apply to future coverage determinations as well as current ones.

Healthcare reform advocates want soaring drug prices curtailed by establishing a “national formulary” enabling the government to get substantial discounts passed on to consumers. TPP won’t allow it.

“Could the inclusion of this Annex in the TPP bolster the case of a pharmaceutical company that is suing the United States,” asked GTW?

Investor-State Dispute Settlement procedures have been included in US trade agreements since the 1990s. Foreign companies may challenge government policies – claiming they potentially curtail future profits. In return, they demand “unlimited sums in taxpayer compensation.”

GTW asked if the Healthcare Annex boosts their case – at the expense of the public interest. Companies could claim government policies compromised their profit expectations and demand compensating reimbursement at taxpayers’ expense.

Much about TPP remains secret – vital information people have a right to know. If enacted, Washington wants it extended to all Asia Pacific Economic Cooperation (APEC) members – about 40% of the world’s population.

Attorney Judit Rius Sanjuan for Doctors Without Borders says TPP “will increase the cost of medicines worldwide, starting with the 12 countries that are negotiating” TPP.

Hugely profitable drug companies want unconstrained rights to charge whatever the market will bear. They claim high prices are needed to compensate for billions of dollars spent for research – without acknowledging how much governments in America and elsewhere pay for, passing on scientific research information to drug companies cost-free.

GTW director Lori Wallach calls the Healthcare Annex leak “the latest example of why fast-tracking the TPP would undermine the health of Americans and the other countries and cost our government more, all to the benefit of pharma’s profits.”

Stephen Lendman lives in Chicago. He can be reached at lendmanstephen@sbcglobal.net. His new book as editor and contributor is titled “Flashpoint in Ukraine: US Drive for Hegemony Risks WW III.”

<http://www.claritypress.com/LendmanIII.html>

Visit his blog site at sjlendman.blogspot.com.

*Listen to cutting-edge discussions with distinguished guests on the Progressive Radio News Hour on the Progressive Radio Network.
It airs three times weekly: live on Sundays at 1PM Central time plus two prerecorded archived programs.*

The original source of this article is Global Research
Copyright © [Stephen Lendman](#), Global Research, 2015

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Stephen Lendman](#)

About the author:

Stephen Lendman lives in Chicago. He can be reached at lendmanstephen@sbcglobal.net. His new book as editor and contributor is titled "Flashpoint in Ukraine: US Drive for Hegemony Risks WW III." <http://www.claritypress.com/LendmanIII.html> Visit his blog site at sjlendman.blogspot.com. Listen to cutting-edge discussions with distinguished guests on the Progressive Radio News Hour on the Progressive Radio Network. It airs three times weekly: live on Sundays at 1PM Central time plus two prerecorded archived programs.

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca